US Health Secretary Alex Azar has outlined progress combating the ongoing opioid crisis, with an update one year on from a pledge from the US President to reduce unnecessary opioid prescriptions, expand treatment, and boost access to naloxone.
In a statement, the US Department of Health & Human Services (HHS) said the total amount of opioids being prescribed monthly has dropped by 34%.
From January 2017 to February 2019, the HHS has led a 484% increase in naloxone prescriptions dispensed by pharmacies, a 23% increase in patients receiving buprenorphine, and a 42% increase in prescriptions for naltrexone.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze